S5 Table Unsolicited AEs with possibility of vaccine contribution with an incidence ≥ 3.0% in any group (29-day follow-up period after vaccination 2) (all enrolled subjects, N = 120)

|  |  |  |
| --- | --- | --- |
| System organ class, Preferred term, (MedDRA 12.0) | Group MM (N = 56) n (%) | Group PM (N = 58) n (%) |
| At least one AE documented | 11 (19.6) | 13 (22.4) |
| General disorders and administration site conditions | 5 (8.9) | 6 (10.3) |
|  Application site haematoma | 0 (0.0) | 2 (3.4) |
|  Injection site nodule | 2 (3.6) | 2 (3.4) |
| Investigations | 5 (8.9) | 2 (3.4) |
|  Lymphocyte count decreased | 2 (3.6) | 0 (0.0) |
| Musculoskeletal and connective tissue disorders | 0 (0.0) | 3 (5.2) |
|  Arthralgia | 0 (0.0) | 2 (3.4) |

AE = adverse event, MedDRA = Medical Dictionary for Regulatory Activities, N = number of documented vaccination periods in the specified group, n = number of vaccination periods with at least one report of one particular unsolicited symptom, % = percentages based on N.

Note: There may be findings in more than one category.

Note: The cut-off of ≥ 3.0% was used for both system organ classes and preferred terms.